Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "clinical-data"

188 News Found

ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'
News | October 16, 2023

ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'

NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy


Emmes acquires VaxTRIALS
News | October 07, 2023

Emmes acquires VaxTRIALS

VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth


EMA accepts LEO Pharma’s MAA for delgocitinib cream in chronic hand eczema
Drug Approval | August 21, 2023

EMA accepts LEO Pharma’s MAA for delgocitinib cream in chronic hand eczema

LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment


Thermo Fisher Scientific to acquire CorEvitas for $912.5 million
News | July 10, 2023

Thermo Fisher Scientific to acquire CorEvitas for $912.5 million

Advances clinical research capabilities with leading regulatory grade registries platform


Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials
Clinical Trials | June 29, 2023

Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials

Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials


Moderna files for FDA authorization of its Covid-19 Vaccine
Drug Approval | June 27, 2023

Moderna files for FDA authorization of its Covid-19 Vaccine

Supply readiness follows months of manufacturing to ensure timely and ample supply


Immutep announces expansion of triple combination therapy in first-line non-small cell lung cancer
Clinical Trials | April 03, 2023

Immutep announces expansion of triple combination therapy in first-line non-small cell lung cancer

Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations


EIP Pharma and Diffusion Pharmaceuticals inks agreement to create CNS-focused company
News | April 03, 2023

EIP Pharma and Diffusion Pharmaceuticals inks agreement to create CNS-focused company

EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging